Pluri (PLUR) Research & Development : $12.57 Mil (TTM As of Mar. 2024)

View and export this data going back to 1991. Start your Free Trial

What is Pluri Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Pluri's Research & Development for the three months ended in Mar. 2024 was $3.09 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was $12.57 Mil.

Pluri Research & Development Historical Data

The historical data trend for Pluri's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pluri Research & Development Chart

Pluri Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Research & Development

Get a 7-Day Free Trial

26.43

21.58

30.07

24.38

15.75

Pluri Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Research & Development	Get a 7-Day Free Trial															4.17	3.52	2.99	2.96	3.09

Pluri Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.57 Mil.

Pluri (NAS:PLUR) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Pluri Research & Development Related Terms

Thank you for viewing the detailed overview of Pluri's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Pluri (PLUR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pluri Inc (NAS:PLUR) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

Y55:Germany

Address

MATAM Advanced Technology Park, Building No.5, Haifa, ISR, 3508409

Website

https://www.pluri-biotech.com

Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility.

Executives

Lorne Kenneth Abony	director	MATAM PARK, BUILDING #5, HAIFA L3 3508409
Zami Aberman	officer: Chief Executive Officer	63 RABUTZKY STREET, RAANANA L3 43220
Varda Shalev	director	MATAM PARK, BUILDING #5, HAIFA L3 3508409
Pinhas Doron Birger	director	MATAM PARK, BUILDING #5, HAIFA L3 3508409
Clover Wolf Capital - Limited Partnership	10 percent owner	BOODENHIMER 24, TEL AVIV L3 6200838
Rami Avraham Levi	director	MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA L3 3508409
Maital Shemesh-rasmussen	director	MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA L3 3508409
Doron Shorrer	director	33 KOREH PLADORR ST, JERUSALEM L3 93393
Isaac Braun	director	9 ZEHARIA STREET, BENE BARAK L3 51540
Yaky Yanay	officer: Chief Financial Officer	ARGAMAN 14, SHIMSHIT L3 17906
Moria Kwiat	director	HAKFAR 11, KIRYAT ONO L3 55525
Israel Ben-yoram	director	24 BARKAN STREET, RISHON LEZION L3 00000
Chen Franco-yehuda	officer: Chief Financial Officer	MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA L3 31905
Mark Germain	director	WELLSFORD REAL PROPERTIES INC, 535 MADISON AVENUE, NEW YORK NY 10022
Erez Egozi	officer: Chief Financial Officer	MATAM PARK, BUILDING 05, HAIFA L3 31905